Compare · AXSM vs BTAI
AXSM vs BTAI
Side-by-side comparison of Axsome Therapeutics Inc. (AXSM) and BioXcel Therapeutics Inc. (BTAI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXSM and BTAI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AXSM is the larger of the two at $12.68B, about 376.6x BTAI ($33.7M).
- AXSM has been more active in the news (23 items in the past 4 weeks vs 6 for BTAI).
- AXSM has more recent analyst coverage (25 ratings vs 12 for BTAI).
- Company
- Axsome Therapeutics Inc.
- BioXcel Therapeutics Inc.
- Price
- -
- -
- Market cap
- $12.68B
- $33.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2018
- News (4w)
- 23
- 6
- Recent ratings
- 25
- 12
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
BioXcel Therapeutics Inc.
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Latest AXSM
- Director Saad Mark E converted options into 1,429 shares, increasing direct ownership by 14% to 11,431 units (SEC Form 4)
- Director Jeffs Roger converted options into 1,429 shares, increasing direct ownership by 2% to 58,939 units (SEC Form 4)
- Director Mahony Susan converted options into 1,429 shares and sold $145,017 worth of shares (600 units at $241.69) as part of a pre-agreed trading plan (SEC Form 4)
- Director Coleman Mark converted options into 1,429 shares and sold $160,107 worth of shares (643 units at $249.00) as part of a pre-agreed trading plan, increasing direct ownership by 3% to 30,389 units (SEC Form 4)
- SEC Form 144 filed by Axsome Therapeutics Inc.
- SEC Form 144 filed by Axsome Therapeutics Inc.
- SEC Form 144 filed by Axsome Therapeutics Inc.
- Axsome Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Axsome Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Coleman Mark
Latest BTAI
- BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
- Chief Scientific Officer Yocca Frank converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,175 units (SEC Form 4)
- Officer Rodriguez Javier converted options into 17,500 shares and sold $7,111 worth of shares (6,560 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,803 units (SEC Form 4)
- Chief Financial Officer Steinhart Richard I converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 68% to 26,300 units (SEC Form 4)
- CEO and President Mehta Vimal converted options into 49,758 shares and sold $21,108 worth of shares (19,419 units at $1.09) as part of a pre-agreed trading plan, increasing direct ownership by 77% to 69,598 units (SEC Form 4)
- SEC Form 144 filed by BioXcel Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by BioXcel Therapeutics Inc.
- BioXcel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by BioXcel Therapeutics Inc.
- BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results